Table 4.
Week 12 | Week 52 | |||||||
---|---|---|---|---|---|---|---|---|
Interaction effect | ASDAS-MI | ASAS40 | BASDAI50 | ASDAS-ID | ASDAS-MI | ASAS40 | BASDAI50 | ASDAS-ID |
MRI*HLA-B27 | 0.5599 | 0.8460 | 0.1517 | 0.6183 | 0.0035* | 0.0014* | 0.0049* | 0.0247* |
Sex*MRI | 0.6680 | 0.3600 | 0.6663 | 0.9666 | 0.0005* | 0.9107 | 0.1873 | 0.0030* |
Age*MRI | 0.8676 | 0.5666 | 0.0916 | 0.2039 | 0.9140 | 0.8291 | 0.4061 | 0.7247 |
CRP*MRI | 0.8584 | 0.4112 | 0.7003 | 0.0681 | 0.0626 | 0.7511 | 0.7955 | 0.4636 |
Sex*CRP | 0.7179 | 0.3568 | 0.5063 | 0.8552 | 0.8904 | 0.7033 | 0.6215 | 0.2282 |
Age*CRP | 0.9958 | 0.4325 | 0.0985 | 0.5441 | 0.0526 | 0.3986 | 0.9907 | 0.3007 |
p-values from the final regression step are reported. *Significant interaction terms included in the final model. ASAS40 Assessment of SpondyloArthritis International Society 40%, ASDAS Ankylosing Spondylitis Disease Activity Score, ASDAS-ID ASDAS inactive disease (ASDAS <1.3), ASDAS-MI ASDAS major improvement (reduction in ASDAS ≥2.0), BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50%, HLA-B27 human leukocyte antigen-B27, MRI magnetic resonance imaging